Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent Approved to Start US Trials of Novel Immunotherapy

publication date: Dec 5, 2018

Suzhou Innovent Biologics was approved to start US clinical trials of its recombinant fully human anti-OX40 mAb, which Innovent intends to test in patients with solid tumors. IBI101, the third Innovent candidate to start US trials, targets the tumor necrosis factor receptor superfamily member 4. Eventually, the company plans to test IBI101 in combination with other immunotherapies, including its own PD-l candidate. At present, there are no approved OX40 mAbs, but based on pre-clinical data, Innovent believes IBI101 causes a larger T cell response than candidates from other companies. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events


China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020